HF
KROS icon

HRT Financial’s Keros Therapeutics KROS Stock Holding History

HRT Financial’s Portfolio KROS Stock Details KROS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-77,002
Closed -$850K – 4820
2026
Q1 		$850K Sell
77,002
-183,889
-70% -$2.84M ﹤0.01% 2165
2025
Q4 		$5.31M Buy
260,891
+218,092
+510% +$3.83M 0.02% 757
2025
Q3 		$677K Buy
+42,799
New +$632K ﹤0.01% 1720
2025
Q2 		– Sell
-14,747
Closed -$150K – 3138
2025
Q1 		$150K Buy
+14,747
New +$171K ﹤0.01% 2084
2024
Q4 		– Sell
-5,807
Closed -$337K – 2857
2024
Q3 		$337K Buy
+5,807
New +$287K ﹤0.01% 1758
2024
Q1 		– Sell
-13,122
Closed -$521K – 2720
2023
Q4 		$521K Buy
+13,122
New +$411K ﹤0.01% 1340
2023
Q1 		– Sell
-21,222
Closed -$1.02M – 2853
2022
Q4 		$1.02M Buy
+21,222
New +$991K 0.01% 950

Other funds holding KROS

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Mackenzie Financial
Mackenzie Financial Toronto Ontario, Ontario, Canada $100B AUM 36.93% 1-Year Est. Return
MAP
Madison Avenue Partners New York $2.32B AUM 132.6% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return

HRT Financial's KROS Position: Q2 2026 in Review

HRT Financial sold out of Keros Therapeutics (KROS) in Q2 2026, closing a stake of 77,002 shares — an estimated $850K sold.

HRT Financial first reported a position in KROS in Q4 2022 and held it in 7 quarters. The position peaked at $5.31M in Q4 2025. 132 funds tracked by Wall St. Rank hold KROS as of Q2 2026.

  • HRT Financial reported no remaining Keros Therapeutics position as of Q2 2026 after selling out during the quarter.
  • HRT Financial sold 77,002 Keros Therapeutics shares in Q2 2026, an estimated $850K.
  • HRT Financial first reported a position in Keros Therapeutics in Q4 2022 and held it in 7 quarters.
  • HRT Financial's Keros Therapeutics position peaked at $5.31M in Q4 2025.
  • 132 funds tracked by Wall St. Rank held Keros Therapeutics as of Q2 2026.

Based on HRT Financial's 13F filing for Q2 2026, filed 14 Aug 2026.